The updated vaccine targets the 'parent strain' of currently circulating variants, and has shown robust cross-reactivity against JN.1 lineage viruses, including KP.2.3, KP.3, KP.3.1.1 and LB.1, said CEO John Jacobs.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/RVqcUHJ
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment